We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
- Authors
Henry, N. L.; Pchejetski, D.; A'Hern, R.; Nguyen, A. T.; Charles, P.; Waxman, J.; Li, L.; Storniolo, A. M.; Hayes, D. F; Flockhart, D. A.; Stearns, V.; Stebbing, J.
- Abstract
<bold>Background: </bold>The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.<bold>Methods: </bold>Patients with breast cancer were enrolled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid mediators using multiplex assays.<bold>Results: </bold>Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than controls (all P<0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases and controls for any of the inflammatory markers tested.<bold>Conclusion: </bold>AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for development of AIMSS.
- Subjects
AROMATASE inhibitors; MUSCULOSKELETAL system abnormalities; ESTROGEN; BREAST cancer patients; ADJUVANT treatment of cancer; CYTOKINES
- Publication
British Journal of Cancer, 2010, Vol 103, Issue 3, p291
- ISSN
0007-0920
- Publication type
journal article
- DOI
10.1038/sj.bjc.6605768